Century Therapeutics (NASDAQ:IPSC) (NASDAQ: IPSC) is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf cell therapies derived from induced pluripotent stem cells (iPSCs). By harnessing proprietary iPSC platforms and genome engineering technologies, Century Therapeutics aims to create allogeneic natural killer (NK), T-cell and macrophage‐like products designed to target solid tumors and hematologic malignancies. The company’s approach emphasizes consistency in manufacturing, scalability and enhanced safety profiles versus traditional autologous therapies.
Founded in 2018 and headquartered in Philadelphia, Pennsylvania, with a research hub in Cambridge, Massachusetts, Century Therapeutics was formed through a collaboration among leading stem cell and cell therapy pioneers. The enterprise integrates expertise in cell biology, immunology and gene editing to advance a pipeline of product candidates. Key programs include CTC-500, an iPSC‐derived NK cell therapy, and CTC-200, an iPSC‐derived T‐cell program, both of which are currently advancing through preclinical and early clinical stages.
Century Therapeutics maintains strategic partnerships with global manufacturing and research organizations to support clinical development and future commercialization. Collaborations with contract development and manufacturing organizations (CDMOs) such as Lonza aim to establish a robust supply chain for large‐scale production of iPSC‐derived therapies. The company also works closely with academic and industry leaders to refine potency assays, streamline gene-editing workflows and optimize product differentiation for specific cancer indications.
Under the leadership of CEO Christopher Vishton, Century Therapeutics is guided by a management team with deep experience in biotechnology, cell therapy development and regulatory affairs. The board of directors and scientific advisory board include seasoned executives and researchers who have played pivotal roles in the advancement of both autologous and allogeneic cell therapy products. With a focus on driving innovative, scalable treatments for patients with high unmet medical needs, Century Therapeutics continues to expand its global footprint and advance its iPSC‐based oncology platform toward meaningful clinical milestones.
